<DOC>
	<DOCNO>NCT02288429</DOCNO>
	<brief_summary>Colistin polymixin antibiotic use treatment multidrug-resistant gram-negative infection . Given limit use colistin previous challenge laboratory assay determine plasma concentration , lack knowledge pharmacokinetic profile colistin . The purpose investigator observational prospective pharmacokinetic cohort study examine steady-state pharmacokinetic pharmacodynamic property intravenous colistimethate sodium cystic fibrosis critically ill patient .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic Pharmacodynamic Properties Intravenous Colistimethate Sodium</brief_title>
	<detailed_description>Colistin , also know polymixin E , peptide antibiotic demonstrates concentration-dependent bactericidal kill gram-negative pathogen include Pseudomonas Acinetobacter . Originally discover 1950s , use limit due concern systemic toxicity include nephrotoxicity neurotoxicity . However , revival colistin use see recent year due increase emergence multidrug-resistant ( MDR ) gram-negative pathogen lack alternative antimicrobial therapy . Colistin administer intravenously colistimethate sodium ( CMS ) , inactive prodrug lack antibacterial activity , hydrolyze active form plasma colistin A colistin B . Prior pharmacokinetic study demonstrate wide range pharmacokinetic/pharmacodynamics ( PK/PD ) find colistin . Variability result attribute unreliable differentiation colistin CMS plasma concentration use microbiological assay , addition procedure result substantial vitro hydrolysis CMS colistin sample preparation . Refined laboratory method high-performance liquid chromatography ( HPLC ) circumvent issue provide opportunity pharmacokinetic profiling . Given scarcity use challenge quantitative assay , pharmacokinetic pharmacodynamic profile colistin poorly characterize particularly amongst cystic fibrosis critically ill patient . Determination parameter patient population vital optimize maximum concentration minimum inhibitory concentration ( Cmax : MIC ) ratio maximal efficacy , minimize adverse effect reduce development bacterial resistance . Previous study examine steady-state pharmacokinetics colistin cystic fibrosis critically ill patient conclude base vitro pharmacodynamics Pseudomonas aeruginosa , current dose recommendation may inadequate achieve desirable Cmax : MIC ratio dose escalation may warrant . The investigator study aim determine steady-state colistin A colistin B concentration cystic fibrosis critically ill patient , evaluate pharmacodynamic parameter relationship microbiologic success , monitor incidence nephrotoxicity . The finding pilot study use develop dose recommendation future pharmacokinetic study colistimethate sodium cystic fibrosis critically ill patient .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Patients â‰¥ 18 year old receive intravenous colistimethate sodium treatment infection Have cystic fibrosis and/or critically ill ( admitted critical care unit ) Pregnancy Breastfeeding Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>critical illness</keyword>
</DOC>